Source: Medicines Authority (MT) Revision Year: 2019 Publisher: Novartis Ireland Limited, Vista Building, Elm Park, Merrion Road, Ballsbridge, Dublin 4, Ireland
Catafast 50 mg powder for oral solution.
| Pharmaceutical Form |
|---|
|
Powder for oral solution. Homogenous, white to light yellow powder. |
The active ingredient is diclofenac potassium. One Catafast sachet contains 50 mg of diclofenac potassium.
| Active Ingredient | Description | |
|---|---|---|
| Diclofenac |
Diclofenac is a non-steroidal anti-inflammatory drug. The mechanism of action of diclofenac in AK may be related to the inhibition of the cycloxygenase pathway leading to reduced prostaglandin E2 (PGE2) synthesis. In addition, immunohistochemistry (IHC) from skin biopsies ac revealed that the clinical effects of diclofenac in AK are primarily due to anti-inflammatory, anti-angiogenic and possibly anti-proliferative effects and apoptosis-inducing mechanisms. |
| List of Excipients |
|---|
|
Potassium hydrogen carbonate |
Sachet hermetically sealed in four directions made of coupled paper/aluminium/polyethylene in an outer carton box.
Pack sizes of 3,9,21 and 30 sachets.
Not all pack sizes may be marketed.
Novartis Ireland Limited, Vista Building, Elm Park, Merrion Road, Ballsbridge, Dublin 4, Ireland
Catafast 50mg powder for oral solution: MA1249/00203
Date of first authorisation: 3rd August 2006
Date of latest renewal: 29th April 2013
| Drug | Countries | |
|---|---|---|
| CATAFAST | Malta, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
